FOR IMPROVED CARE AND REDUCED COSTS
The frequency of diagnostic errors in oncologic pathology has been reported as high as 15%.1 In a study of hematologic malignancies, a major revision to the diagnosis was rendered in as many as one in five cases.2 Such errors waste valuable healthcare resources and cost precious time for patients. Unlike non-specialty laboratory providers, the Genoptix workflow is tailored to oncology patient case management. Each case is supervised by a hematopathologist who manages, interprets, and integrates test results into a comprehensive assessment. Our process allows for greater efficiency, leading to accurate and timely diagnoses and effective cost containment by eliminating unnecessary testing during the full episode of care.
Inaccurate diagnoses can cost members repeated tests, inappropriate treatments, hospitalizations, or worse. By avoiding these risks through accurate results, Genoptix is significantly associated with greater health economic benefits and outcomes.3-5 Our process reduces cost and improves patient care by avoiding repeat tests, excessive time to diagnosis and treatment, unnecessary physician visits, inappropriate drug treatment, and potential precipitation or exacerbation of comorbidities. A national retrospective study found that Genoptix patients had less risk of change in diagnosis, fewer repeat marrow biopsies, and fewer changes in chemotherapy over the course of one year post bone marrow than non-specialized local or large lab patients.3-5
Read more by downloading the BMC Clinical Pathology article Diagnosing testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes.
Optimal management of hematologic malignancies requires an early, accurate, complete, and clear diagnosis. Hematologic malignancies, however, are frequently misdiagnosed. Studies have demonstrated misdiagnosed in up to 27% of leukemia, 18% of lymphoma, and 75% of Bukitt lymphoma cases. Read more by downloading the American Health & Drug Benefits article Lowering Costs Through Effective Hematologic Malignancy Diagnosis.